Customize your JAMA Network experience by selecting one or more topics from the list below.
Steinberg MH, Barton F, Castro O, et al. Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment. JAMA. 2003;289(13):1645–1651. doi:10.1001/jama.289.13.1645
Author Affiliations: Boston University School of Medicine, Center of Excellence in Sickle Cell Disease, Boston Medical Center, Boston, Mass (Dr Steinberg); University of Mississippi School of Medicine, Jackson (Drs Steinberg, and Bigelow); Maryland Medical Research Institute, Baltimore (Ms Barton, Dr Terrin); Center for Sickle Cell Disease, Howard University School of Medicine, Washington, DC (Dr Castro); University of Miami School of Medicine, Miami, Fla (Dr Pegelow); Thomas Jefferson University, Philadelphia, Pa (Dr Ballas); Medical College of Georgia, Augusta (Dr Kutlar); University of North Carolina, Chapel Hill (Drs Orringer and Ataga); New York Methodist Hospital, Brooklyn (Dr Bellevue); Hospital for Sick Children, Toronto, Ontario (Dr Olivieri); Sickle Cell Center, Emory University, Atlanta, Ga (Dr Eckman); University of Medicine and Dentistry of New Jersey, Newark (Dr Varma); Roosevelt Medical Center, New York, NY (Dr Ramirez); University of Alabama at Birmingham (Dr Adler); Virginia Commonwealth University, Richmond (Dr Smith); University of Pittsburgh, Pittsburgh, Pa (Dr Carlos); Duke University School of Medicine, Durham, NC (Dr DeCastro); University of Illinois at Chicago (Dr Saunthararajah); Michael Reese Medical Center, Chicago, Ill (Dr Telfer); Children's Hospital and Research Center at Oakland, Oakland, Calif (Dr Vichinsky); University of California at San Francisco (Dr Claster); Rainbow Babies and Children's Hospital, Cleveland, Ohio (Dr Shurin); Brigham and Women's Hospital, Boston (Dr Bridges); National Heart, Lung, and Blood Institute, Bethesda, Md (Drs Bonds and Waclawiw). Dr Pegelow is deceased.
Context Hydroxyurea increases levels of fetal hemoglobin (HbF)
and decreases morbidity from vaso-occlusive complications in patients
with sickle cell anemia (SCA). High HbF levels reduce morbidity and
Objective To determine whether hydroxyurea attenuates mortality in
patients with SCA.
Design Long-term observational follow-up study of mortality in
patients with SCA who originally participated in the randomized,
double-blind, placebo-controlled Multicenter Study of Hydroxyurea in
Sickle Cell Anemia (MSH), conducted in 1992-1995, to
determine if hydroxyurea reduces vaso-occlusive events. In the MSH
Patients' Follow-up, conducted in 1996-2001, patients could continue,
stop, or start hydroxyurea. Data were collected during the trial and in
the follow-up period.
Setting Inpatients and outpatients in 21 sickle cell referral
centers in the United States and Canada.
Patients Two-hundred ninety-nine adult patients with frequent
painful episodes enrolled in the follow-up. Follow-up data through
May 2001 were complete for 233 patients.
Intervention In the MSH, patients were randomly assigned to
receive hydroxyurea (n = 152) or placebo (n = 147).
Main Outcome Measure Mortality, HbF levels, painful episodes,
acute chest syndrome, and blood cell counts. The randomized trial was
not designed to detect specified differences in mortality.
Results Seventy-five of the original 299 patients died, 28% from
pulmonary disease. Patients with reticulocyte counts less than
250 000/mm3 and hemoglobin levels lower than 9 g/dL
had increased mortality (P = .002).
Cumulative mortality at 9 years was 28% when HbF levels were lower
than 0.5 g/dL after the trial was completed compared with 15% when HbF
levels were 0.5 g/dL or higher
(P = .03 ). Individuals who had acute
chest syndrome during the trial had 32% mortality compared with 18%
of individuals without acute chest syndrome
(P = .02). Patients with 3 or more
painful episodes per year during the trial had 27% mortality compared
with 17% of patients with less frequent episodes
(P = .06). Taking hydroxyurea was
associated with a 40% reduction in mortality
(P = .04) in this observational follow-up with
self-selected treatment. There were 3 cases of cancer, 1 fatal.
Conclusions Adult patients taking hydroxyurea for frequent painful
sickle cell episodes appear to have reduced mortality after 9 of years
follow-up. Survival was related to HbF levels and frequency of
vaso-occlusive events. Whether indications for hydroxyurea treatment
should be expanded is unknown.
Create a personal account or sign in to: